Navigation Links
In the lab and clinic, VCU Massey develops a new therapy for blood cancers
Date:6/2/2011

Richmond, Va. (June 2, 2011) Clinical researchers at VCU Massey Cancer Center have successfully completed a Phase I clinical trial evaluating a combination of the drugs Bortezomib and Alvocidib in patients with relapsed or refractory blood cancers, paving the way for a Phase II clinical trial to test the safety and effectiveness of the new therapy.

Reported in the journal Clinical Cancer Research, the study determined the maximum tolerated dose with acceptable side effects for this novel drug combination. The trial represented the first time a proteasome inhibitor such as Bortezomib was combined with a cell cycle inhibitor such as Alvocidib to treat patients with cancer.

Proteasome inhibitors work by blocking the action of proteasomes, which are large protein complexes that help destroy proteins that are no longer needed by the cell. Cell cycle inhibitors disrupt the sequence of events that allow cells to undergo cell division and duplication. They also have the ability to block gene transcription.

The trial included 16 patients who had either indolent (non-aggressive) non-Hodgkin's lymphoma, mantle cell lymphoma or multiple myeloma. After they received the treatments over a 21-day cycle, there were two complete responses, meaning that all detectable traces of the cancer were gone, and five partial responses.

"Therapeutic responses tend to be rare in Phase I trials, but 44 percent of our patient sample responded to the therapy. Interestingly, some patients who previously had no response to Bortezomib, or progressed after Bortezomib therapy, responded to the combination," says Beata Holkova, M.D., a hematologist-oncologist at VCU Massey and co-investigator on this clinical trial. "Because of the small patient sample size, we can't draw definitive conclusions about the effectiveness of the therapy, but we were quite encouraged by the results."

The patients received Bortezomib intravenously on days 1, 4, 8 and 11 and Alvocidib on days 1 and 8. Bortezomib's therapeutic dose alone was not tested because it has already been established and approved to treat certain blood cancers. However, for Alvocidib, the researchers escalated the dose until the maximum tolerated dose was identified. The same researchers are also currently completing a second Phase I clinical trial testing a different delivery schedule of Alvocidib. Although not yet completed, the initial results of this trial appear comparable to the present study.

"This is one of the first trials of its type in which two targeted agents which interfere with two very different biological processes are being combined to treat patients with blood cancers," says co-investigator Steven Grant, M.D., associate director for translational research, co-program leader of Developmental Therapeutics and professor of internal medicine at VCU Massey.

The rationale for this study was developed in Grant's laboratory when synergistic interactions between proteasome and cell cycle inhibitors in malignant blood cancer cells were discovered by Yun Dai, M.D., Ph.D., associate professor of internal medicine at VCU Massey. This laboratory research established the basis for a V Foundation Translational Research Award, which with additional funding from the National Institutes of Health provided the resources necessary to translate the laboratory findings into clinical trials.

Moving forward, the researchers are working with the NCI to develop a Phase II clinical trial to test the effectiveness of this drug therapy. The trial will be conducted in collaboration with multiple institutions to compare the effectiveness of fixed doses of the drug combination in a larger patient population.


'/>"/>

Contact: John Wallace
wallacej@vcu.edu
804-628-1550
Virginia Commonwealth University
Source:Eurekalert

Related medicine news :

1. Kreativ Dental Clinic, Offering Dental Implant and Dental Services Abroad, Launches 3D Virtual Tours Online
2. VCU Massey research finds new link between inflammation and cancer
3. Key leukemia defense mechanism discovered by VCU Massey Cancer Center
4. VCU Massey Cancer Center awarded $2.4 million grant from Virginia Tobacco Commission
5. Novel therapy for metastatic kidney cancer developed at VCU Massey Cancer Center
6. VCU Massey first to combine targeted agents to kill multiple myeloma cells
7. VCU Massey Cancer Center finds new biomarker that predicts breast cancer relapse
8. Personal Best Develops Workplace Weight Loss Program
9. M. D. Anderson develops tool to measure severity of chronic graft-vs.-host disease symptoms
10. UD team develops new method for producing proteins critical to medical research
11. UMass Memorial health care develops fully integrated EMR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... Multiple award ... been family-owned and operated for over 35 years. Maintaining core values of exceptional customer ... their success and made them a leading name in San Diego plumbing, and other ...
(Date:5/6/2016)... ... May 06, 2016 , ... In honor ... education and corporate training, and the National Military Family Association, a nonprofit that ... as the second full-tuition scholarship recipient of 2016. , “Being awarded this ...
(Date:5/6/2016)... ... 2016 , ... “ Crossing Over: Affirmations of Faith in the Midst of ... allowed those holding vigil to glimpse into the supernatural as their lives ended. With ... spiritually and practically gain insight into providing care to terminal patients. , “I ...
(Date:5/5/2016)... ... May 05, 2016 , ... While the practice and profession ... the impact our aging population has on communities and resources. Aging Life Care plays ... and face age-related challenges. , Aging Life Care is a holistic, client-centered approach ...
(Date:5/5/2016)... ... May 05, 2016 , ... Textile Exchange is excited ... for public stakeholder review. The stakeholder review is an important opportunity for interested parties ... and delivers value to the wool industry., The RWS is intended to be a ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... 4, 2016  Compass Diversified Holdings (NYSE: ... owner of leading middle market businesses, announced today its ... 31, 2016. First Quarter 2016 Highlights ... ("CAD" or "Cash Flow") of $13.6 million for the ... of $15.0 million for the first quarter of 2016; ...
(Date:5/4/2016)... Yissum Research Development Company ... that it had signed an exclusive world-wide licensing and ... novel protein degradation and immunomodulatory drugs for cancer and ... candidates representing first-in-class therapy for hematologic and solid malignancies. ... The novel technology was developed by Yinon ...
(Date:5/4/2016)... 2016 Research and ... Acute Myeloid Leukemia Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... and Competitive Landscape Highlights 2016, provides comprehensive ... Acute Myeloid Leukemia epidemiology, Acute Myeloid Leukemia ...
Breaking Medicine Technology: